TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Follicular fluid concentrations of fetuin A and fetuin B
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lung ultrasound at 30 minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lung ultrasound at 1 hour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lung ultrasound at 2 hour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lung ultrasound at 4 hour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lung ultrasound at 6 hour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Non-invasive blood pressure (NIBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of missed meal boluses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Clinical response to Metformin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Cytokine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Complete Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Qualified Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neuromuscular transmission dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percent Change From Baseline in Pain Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: muscle strength of knee extensor and plantarflexor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: maximum rate of oxygen consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of metabolic decompensation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Participants Who Achieved Investigator's Global Assessment - Treatment Success (IGA-TS)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Proportion of Participants With Infusion-related Reaction (IRR)
Endpoint domain: Adverse events/effects
Primary endpoint: Response Rate Based on Overall Treatment Effect (OTE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Controlled Attenuation Parameter (CAP) Accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PASI100
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: number of patients with low tumor regression grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: number of patients with surgical complications
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of subjects free from symptomatic parasitemic subjects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in substance use frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Utilization of nicotine for treating hunger pain
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Glycosylated hemoglobin (HbgA1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: airway response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Maximum tolerated dose and RP2D
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events as assessed by (CTCAE) version 4.0
Endpoint domain: Adverse events/effects
Primary endpoint: Response Proportion
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Composite outcome of childbirth variables
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: change of prenatal and postnatal stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change of prevalence of antibodies against SARS-CoV-2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in SARS-CoV-2 seroconversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: cellular morphology and density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: detection of breast shrinkage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: detection of irregularity of breast shape
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Steady state plasma concentration - levodopa
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under plasma concentration versus time curve (AUC) - levodopa
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Coefficient of variation (COV) for plasma levodopa concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of positive antiphospholipid antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Occurrence of chronic GVH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Maternal nipple pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Infant breast feeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cervical spine injuries and fractures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Opioid Consumption During First Postoperative Week
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Average Pain During First Postoperative Week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient's wellbeing
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Embryo survival rate after freezing
Endpoint domain: Mortality/survival
Primary endpoint: Change in Maximum Platelet Aggregation (MPA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Reductions in hospitalization
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Change in KABC-II scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Weight-for-Length Z-Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: amount of backup breaths by the ventilator
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in IRS-1/PI3K/AKT Pathway Activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Positioning success rate of double lumen tube and bronchial blocker
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: incidence and severity of systemic adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients with plasma HIV RNA < 50 copies/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of withdrawal from adjuvant Tamoxifen due to adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with detectable intratumoral gemcitabine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Neer test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Empty can test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hawkins Kennedy test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Oswestry Disability Index (ODI) Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Neonatal growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: American College of Rheumatology (ACR) 20 response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Disease Activity Score DAS28 [hsCRP]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the quality of life, function and work as measured by the Short-Form Health Survey Version 2.0 (SF36v2)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Tissue distribution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DNA methylation patterns in sperm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: small RNA content in sperm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sperm histone retention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BMI, hip and waist girth of adolescent/young adult children
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: general health of adolescent/young adult children
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage change in Bone Mineral Density at the lumbar spine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Upper Limb Strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical biochemistry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Adverse events and tolerability
Endpoint domain: Adverse events/effects
Primary endpoint: YMRS total score change from baseline to Day 21
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in serum bicarbonate concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in exam score from baseline
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Reduction of Hyperreflexia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Sleep Activity
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Length of Awake Time
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Peripheral blood pro-resolving mediator levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse Drug Events within 30 days post-discharge
Endpoint domain: Adverse events/effects
Primary endpoint: Progression to invasive squamous cell carcinoma or neoplastic skin tumors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: % of Participants With Moderate to Severe Diarrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Corneal Staining (Inferior Region)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Erector Spinae Muscle Length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Numeric Pain Rating Scale (NPRS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of emitted dose deposited in the lungs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Hypoxic Episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Identification of etiology of vertebral osteomyelitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of participants with adverse events (AEs), adverse events of interest (AEIs), and serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Change from Baseline in the performance status (PS) score established by the Eastern Cooperative Oncology Group (ECOG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of grade 3 and 4 adverse events related to infection
Endpoint domain: Adverse events/effects
Primary endpoint: Number of male cercariae for detectable CAA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of T cell therapy
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma concentration-area under time curve (AUC0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve (AUC(0 to Infinity))
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Peak Plasma Concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Subjects With Inhibitory Anti-C1-esterase-inhibitor Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Treatment failure (flares of GVHD requiring immunosuppressive drug therapy)
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of Participants With Eyelid Erythema
Endpoint domain: Adverse events/effects
Primary endpoint: Change in UP/CR ratio with Acthar gel alone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in UP/CR ratio with Acthar gel in combination with Tacrolimus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Proportion of women delivering low birth weight babies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Disengagement from care
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Hand Joint Position Sense
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in Ocular motor nerve function subscale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Neuroinflammation distribution pattern
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean Monthly Duration of Clinically Significant Arrhythmia (CSA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Speed in social working memory task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of deception detection based on self-report
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Self-reported perceptions of trust and threat
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Self-reported empathy and altruistic behavior
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of Patients Alive and Without Progressive Disease for ≥6 Months
Endpoint domain: Mortality/survival
Primary endpoint: Change from Baseline in weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of cancer representations in children
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of health representations in children
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Dynamic Hyperinflation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Maslach Burnout Inventory - Human Services Survey (MBI-HSS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence rate of adverse event of Hib vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: Post operative delirium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Early post operative cognitive dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: 45 days post operative cognitive dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Late post operative cognitive dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Presence of neuropathic pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Care consumption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Radiographic change in dental cavity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Death or Disease Progression
Endpoint domain: Mortality/survival
Primary endpoint: Rate of Major and Minor Hypoglycaemic Episodes
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of Nocturnal Major and Minor Hypoglycaemic Episodes
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical Rating Scale for Tremor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Severity of Device and Procedure related complications
Endpoint domain: Adverse events/effects
Primary endpoint: Proportions of HER2 & PD-L1 positive CTC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence rate of ctDNA deletion, amplification, insertion and other types of variation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumor associated proteins expression level of tumor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Modified Oswestry Low Back Pain Disability Index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change of 11-point Numeric Pain Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Body Pain diagram
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hypertension screening participation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood pressure monitoring increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of ISIS 183750
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Maximum Tolerated Dose of Irinotecan
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in elF4E mRNA Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in elF4e Protein Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Major Adverse Cerebral and Cardiovascular Events
Endpoint domain: Mortality/survival
Primary endpoint: Quality of life - Seattle Angina Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in PO2 values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Oxygen in tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraosseous Infusion Flow rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional Benefit
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Pain Level Changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cure Rates of Superficial BCC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: number of uNK cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Clearance time with five diagnostic tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of recurrent infection with HRP2 and LDH-based Rapid diagnostic tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in Inflammatory Lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Progression rate of joint space narrowing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in carotid stiffness (elasticity and distensibility)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Behavioral Activation for Depression Scale-Short Form
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Area under the plasma concentration curve after the first and last multiple oral dose (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak plasma concentration (Cmax) after the first and last multiple oral dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Terminal elimination halflife (t½) for SHR0534 after the last multiple oral dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in the concentrations of blood glucose and insulin after multiple oral dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement in Lower Tract Symptoms (LUTS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes from baseline of clinical parameters on CBC/differential, chemistry panel
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidence and severity of local i.v.-site reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Caspase 3 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postoperative pain assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hemodynamic assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: relieving symptoms of DED
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improving signs of DED
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes